<SEC-DOCUMENT>0001193125-18-332339.txt : 20181121
<SEC-HEADER>0001193125-18-332339.hdr.sgml : 20181121
<ACCEPTANCE-DATETIME>20181121160346
ACCESSION NUMBER:		0001193125-18-332339
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20181121
DATE AS OF CHANGE:		20181121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DEXCOM INC
		CENTRAL INDEX KEY:			0001093557
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330857544
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-228495
		FILM NUMBER:		181198220

	BUSINESS ADDRESS:	
		STREET 1:		6340 SEQUENCE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8582000200

	MAIL ADDRESS:	
		STREET 1:		6340 SEQUENCE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d649190d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-228495</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class of securities</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to be registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount&nbsp;to&nbsp;be<BR>registered (1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>maximum<BR>offering&nbsp;price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>per unit (2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>maximum<BR>aggregate&nbsp;offering<BR>price (2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>registration&nbsp;fee</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Stock, $0.001 par value per share, issuable at the
election of DexCom, Inc.</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1,840,943</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$129.04</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$237,555,285</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Stock, $0.001 par value per share, issuable at the
election of DexCom, Inc. upon achievement of milestones, subject to certain closing conditions</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2,025,036</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$129.04</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$261,310,646</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Total</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3,865,979</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$498,865,931</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$60,463</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), this
Registration Statement shall also cover any additional shares of common stock which become issuable by reason of any stock dividend, stock split or other similar transaction effected without the receipt of consideration that results in an increase
in the number of outstanding shares of the registrant&#146;s common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In accordance with Rule 457(c) under the Securities Act, the aggregate offering price of the registrant&#146;s
common stock is estimated solely for the purpose of calculating the registration fees due for this filing. For the initial filing of this Registration Statement, this estimate was based on the average of the high and low sales price of the
registrant&#146;s common stock reported by The Nasdaq Global Select Market on November&nbsp;19, 2018. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>PROSPECTUS SUPPLEMENT </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To prospectus dated November&nbsp;20, 2018) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g649190g14l76.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>3,865,979 Shares of Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement relates to the issuance by DexCom, Inc. of up to 3,865,979 shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may be issued pursuant to that certain Amended and Restated Collaboration and License Agreement, or the Collaboration and License
Agreement, to be entered into by and between DexCom, Inc., or DexCom, Verily Life Sciences LLC (an Alphabet Company) and Verily Ireland Limited, collectively referred to as Verily, and the Common Stock Purchase Agreement, or the Purchase Agreement,
to be entered into by and among DexCom, Verily Life Sciences LLC and Onduo, LLC, or Onduo, a joint venture partially owned by Verily. Under the terms of the Collaboration and License Agreement, we will be required to make an upfront payment to
Verily and Onduo of 1,840,943 shares of our common stock and we may be required to make milestone payments to Verily and/or Onduo which, if all such payments become due under the Collaboration and License Agreement, would equal an aggregate of
2,025,036 shares of our common stock. At our option, we may pay cash to Verily and/or Onduo or issue shares of our common stock for the upfront and milestone payments pursuant to the Collaboration and License Agreement. We intend to elect in the
Purchase Agreement to make the upfront payment in shares of our common stock. The number of shares that may be issued is based on the price per share of $135.7999, which is the volume weighted average trading price of our common stock during the
period of 15 consecutive trading days ending on the date of the Collaboration and License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock trades on The
Nasdaq Global Select Market under the symbol &#147;DXCM.&#148; On November&nbsp;19, 2018, the closing sale price of our common stock, as reported on The Nasdaq Global Select Market, was $121.31 per share. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>INVESTING IN OUR COMMON STOCK INVOLVES RISKS. YOU SHOULD CAREFULLY CONSIDER THE RISKS DESCRIBED UNDER &#147;<A HREF="#supptx649190_3">RISK FACTORS
</A>&#148; BEGINNING ON PAGE S-8 OF THIS PROSPECTUS SUPPLEMENT, AS WELL AS OTHER INFORMATION CONTAINED OR INCORPORATED BY REFERENCE IN THIS PROSPECTUS SUPPLEMENT BEFORE MAKING A DECISION TO INVEST IN OUR SECURITIES. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities or
determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus supplement is November&nbsp;20, 2018. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx649190_1">About this Prospectus Supplement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx649190_2">Prospectus Supplement Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx649190_3">Risk Factors </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx649190_4">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx649190_5">Description of Amended and Restated Collaboration and License Agreement
 and Common Stock Purchase Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx649190_6">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx649190_7">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx649190_8">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx649190_9">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx649190_10">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx649190_11">Incorporation of Documents by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_2">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_4">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_6">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_7">Description of Debt Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_8">Description of Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_9">Description of Subscription Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_10">Description of Units</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_11">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_12">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_13">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_14">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_15">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx649190_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;20, 2018, we, as a &#147;well-known seasoned issuer&#148; as defined in Rule 405 under the Securities Act of 1933, as
amended, or the Securities Act, filed with the Securities and Exchange Commission, or SEC, an automatic registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> (File No.
<FONT STYLE="white-space:nowrap">333-228495),&nbsp;which</FONT> registration statement became automatically effective upon filing. Under this shelf registration process, we may, from time to time, sell common stock and other securities, of which
this offering is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document is in two parts. The first part is the prospectus supplement, including the documents incorporated
by reference herein, which describes the specific terms of this offering and also adds to and updates the information contained in the accompanying prospectus and the documents incorporated by reference. The second part, the accompanying prospectus,
including the documents incorporated by reference therein, provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. Before
you invest, you should carefully read this prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein, as well as the additional information described in this prospectus supplement under
&#147;Where You Can Find More Information.&#148; This prospectus supplement may add, update or change information contained in the accompanying prospectus. To the extent that any statement we make in this prospectus supplement is inconsistent with
statements made in the accompanying prospectus or any documents incorporated by reference therein, the statements made in this prospectus supplement will be deemed to modify or supersede those made in the accompanying prospectus and such documents
incorporated by reference therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions
where offers and sales are permitted. The distribution of this prospectus supplement and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this
prospectus supplement must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus supplement outside the United States. This prospectus supplement does not
constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement by any person in any jurisdiction in which it is unlawful for such person to make such
an offer or solicitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the documents described herein,
but reference is made to the actual documents for complete information. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this
prospectus is a part, and you may obtain copies of those documents as described below under the heading &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unless the context otherwise indicates, references in this prospectus supplement to &#147;DexCom&#148;, &#147;we&#148;, &#147;our&#148;,
&#147;us&#148; and &#147;the Company&#148; refer, collectively, to DexCom, Inc., a Delaware corporation.</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own various U.S. federal
trademark registrations and applications and unregistered trademarks, including our corporate logo. This prospectus supplement, the accompanying prospectus and the information incorporated herein and therein by reference contains references to
trademarks, service marks and trade names referred to in this prospectus supplement, the accompanying prospectus and the information incorporated herein and therein, including logos, artwork, and other visual displays, may appear without the <SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or <SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> symbols, but such references are not intended to indicate, in any way, that we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, service marks or trade names. We do not intend our use or
display of other companies&#146; trade names, service marks or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. All trademarks, service marks and trade names included or incorporated by reference
into this prospectus supplement, accompanying prospectus or any related free writing prospectus are the property of their respective owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx649190_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained in other parts of this prospectus supplement, the accompanying prospectus and the information
incorporated herein and therein from our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, and our other filings with the SEC listed below under the heading &#147;Incorporation of Certain
Information by Reference.&#148; This summary does not contain all of the information you should consider in making your investment decision. Before deciding to invest in our securities, you should read the entire prospectus supplement, accompanying
prospectus and any related free writing prospectus, and the information incorporated by reference herein in their entirety. You should carefully consider, among other things, the matters discussed under the heading &#147;Risk Factors&#148; contained
in this prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. Some of the statements in this prospectus supplement and accompanying
prospectus constitute forward-looking statements that involve risks and uncertainties. See &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a medical device
company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for use by people with diabetes and by healthcare providers for the treatment of people with diabetes. We received approval
from the Food and Drug Administration, or FDA, and commercialized our first product in 2006, and launched our latest generation system, the DexCom G6<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Continuous Glucose Monitoring System, or
G6, this year. We believe our CGM systems are currently the most consistently accurate available for continuous glucose monitoring. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>DexCom G6<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2018, we received approval from the FDA for the G6, which is indicated by the FDA for use as both a standalone CGM and for integration
into automated insulin dosing (AID) systems. The G6 is the first CGM to receive this classification from the FDA. Along with this classification, the FDA is establishing criteria, called special controls, which outline requirements for assuring CGM
accuracy, reliability and clinical relevance, as well as describe the type of studies and data required to demonstrate acceptable CGM performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The G6 is designed to allow our transmitter to run the Software 505 algorithm, and to communicate directly to a patient&#146;s mobile device,
including iPhone<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, iPod touch<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, iPad<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, or certain Android mobile digital
devices. The G6 transmitter has a labeled useful life of three months. Data from the G6 can be integrated with DexCom CLARITY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, our cloud-based reporting software, for personalized, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">easy-to-understand</FONT></FONT> analysis of trends that may improve diabetes management. In June 2018, we received Conformit&eacute; Europ&eacute;enne Marking, or CE Mark, approval for the
G6, which allows us to sell the system in the European Union, Australia, New Zealand and the countries in Asia and Latin America that recognize the CE Mark. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sensor is inserted by the user and is intended to be used continuously for up to ten
days, after which it may be replaced with a new disposable sensor. Our transmitter is reusable until it reaches the end of its battery life. Our receiver is reusable. As we establish an installed base of customers using our products, we expect to
generate an increasing portion of our revenues through recurring sales of our disposable sensors. The G6 carries forward important features of prior generation DexCom CGM systems: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Continuous Glucose Readings:</B> Automatically sends glucose readings to a DexCom receiver or compatible smart
device every five minutes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Mobile App and Sharing:</B> Compatibility with smart device applications allows for sharing glucose
information with up to five people for added support. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Customizable Alarms and Alerts:</B> Personalized alert schedule immediately warns the wearer of pending
dangerous high and low blood sugars. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Coverage:</B> The G6 is covered by commercial insurers that reimburse for the G5 Mobile as well as Medicare.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The G6 also has a number of new or improved features compared to our prior generation devices: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Fingerstick Elimination:</B> No fingersticks are needed for calibration or diabetes treatment decisions.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Easy Sensor Applicator</B>: Complete redesign of the sensor applicator allows for <FONT
STYLE="white-space:nowrap">one-touch,</FONT> simple insertion. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Discreet and Low Profile:</B> A redesigned transmitter with a 28% lower profile than previous generation
DexCom CGMs makes the device comfortable and easy to wear under clothing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Acetaminophen Blocking:</B> New feature allows for more accurate glucose readings with no medication
interference. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Predictive Low Alert</B>: New alert feature predicts hypoglycemia before it hits to help avoid dangerous low
blood sugar events. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Extended <FONT STYLE="white-space:nowrap">10-Day</FONT> Sensor</B>:
<FONT STYLE="white-space:nowrap">10-day</FONT> sensor allows for 43% longer wear than previous generation DexCom CGMs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except with respect to the foregoing, the G6 is equivalent to our prior generation CGM systems in its technical capabilities and its
regulatory requirements and indications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>DexCom G5<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Mobile </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2015, we received approval from the FDA for the DexCom G5<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Mobile Continuous
Glucose Monitoring System, also referred to as the G5 Mobile. As with the G6, the G5 Mobile is designed to allow our transmitter to run the Software 505 algorithm, and to communicate directly to a patient&#146;s mobile device, including iPhone<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, iPod touch<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, iPad<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, or certain Android mobile digital devices. The G5 Mobile
transmitter has a labeled useful life of three months. Data from the G5 Mobile can be integrated with DexCom CLARITY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>. In September 2015, we launched the G5 Mobile in certain countries in Europe.
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to the G6, the sensor is inserted by the user and is intended to be used
continuously for up to seven days, after which it may be replaced with a new disposable sensor. Our transmitter is reusable until it reaches the end of its battery life. Our receiver is reusable. In December 2016, the FDA approved the G5 Mobile as
the first CGM system in the United States to have a <FONT STYLE="white-space:nowrap">non-adjunctive</FONT> indication. The <FONT STYLE="white-space:nowrap">non-adjunctive</FONT> indication expands the lawfully permitted use of the G5 Mobile as a
replacement to finger stick glucose testing for diabetes treatment decisions. With the new label indication, the G5 Mobile only requires two finger pricks per day for calibration. In the countries and regions outside of the United States that
recognize the CE Mark, as well as the United States and Canada, the G5 Mobile also does not require confirmatory finger sticks when making treatment decisions, although a minimum of two finger sticks a day remain necessary for calibration. Approval
of the <FONT STYLE="white-space:nowrap">non-adjunctive</FONT> indication also was an important and necessary step in enabling people with Medicare to access CGM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except with respect to the foregoing, the G5 Mobile is equivalent to our other generation CGM systems in its technical capabilities and its
regulatory requirements and indications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>DexCom G4<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> PLATINUM </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DexCom G4 PLATINUM CGM system replaced our DexCom SEVEN PLUS system beginning in 2012, when it was approved for up to seven days of
continuous use by adults with diabetes. Since 2012, we have marketed the DexCom G4 PLATINUM under a CE Mark in the European Union, Australia, New Zealand and the countries in Asia and Latin America that recognize the CE Mark, and in the United
States with approval from the FDA. We received approvals for a pediatric indication under the CE Mark in February 2013 and from the FDA in February 2014, enabling us to market and sell this system to persons two years old and older who have
diabetes. In June 2014, we received approval from the FDA for an expanded indication for the DexCom G4 PLATINUM for professional use, which allows healthcare professionals to purchase the DexCom G4 PLATINUM system for use with multiple patients.
Healthcare professionals can use the insights gained from a DexCom G4 PLATINUM professional session to adjust therapy and to educate and motivate patients to modify their behavior after viewing the effects that specific foods, exercise, stress and
medications have on their glucose levels. In October 2014, we launched our Software 505 for the DexCom G4 PLATINUM, an algorithm which enabled our systems to achieve a single digit MARD&#151;a measure of the accuracy of continuous glucose
monitoring. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>DexCom Share<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2015, we received approval from the FDA for the DexCom G4 PLATINUM with Share and began commercializing this product in the United States in
the first quarter of 2015 using a secure wireless connection between a patient&#146;s G4 PLATINUM receiver and an app. We now offer this feature directly from the transmitter through the G6 and the G5 Mobile apps. The DexCom Share remote monitoring
system uses an app on the patient&#146;s iPhone, iPod touch, iPad, Apple Watch<I><SUP STYLE="font-size:85%; vertical-align:top">TM</SUP></I> or Android mobile digital device to transmit glucose information to apps on the mobile devices of up to five
designated recipients, or &#147;followers&#148;, who can remotely monitor a patient&#146;s glucose information and receive alert notifications anywhere they have an Internet or cellular connection. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Data&nbsp;&amp; Insulin Delivery Collaborations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into multiple collaboration agreements that leverage our technology platform to integrate our continuous glucose monitoring
products with insulin delivery systems. The general purpose of these development and commercial relationships is to integrate our technology into the insulin pump or pen product offerings of the respective partner, enabling the partner&#146;s
insulin delivery device to receive and display glucose readings from our transmitter and, in some cases, use the glucose readings for semi-automated insulin delivery. Currently, we have announced material insulin delivery partnerships with Eli
Lilly, Insulet, Novo Nordisk and Tandem. In addition to these major partners, we are working with other companies that are pursuing varying strategies surrounding semi-automated insulin delivery and data analytics to improve outcomes and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ease-of-use</FONT></FONT> in diabetes management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Verily Collaboration
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;20, 2018, we will enter into an amended and restated Collaboration and License Agreement with Verily, amending and
restating the original agreement from August 2015, as amended in October 2016. Pursuant to the Collaboration and License Agreement, we and Verily will agree to continue to jointly develop a series of next-generation continuous glucose monitoring
products. The Collaboration and License Agreement will provide us with an exclusive license to use certain intellectual property of Verily related to the development, manufacture and commercialization of the products contemplated under the
Collaboration and License Agreement. The Collaboration and License Agreement will provide for one executive sponsor from each of us and Verily to meet periodically and make decisions by consensus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Future Products </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan
to develop future generations of technologies focused on improved performance and convenience and that will enable intelligent insulin administration. We also are aggressively exploring how to extend our product portfolio to other categories of
people with diabetes including those with Type 2 diabetes that are <FONT STYLE="white-space:nowrap">non-insulin</FONT> using, people with <FONT STYLE="white-space:nowrap">pre-diabetes</FONT> and people who are obese. Over the longer term, we plan to
develop networked platforms with open architecture, connectivity and transmitters capable of communicating with other devices and software systems. We also intend to expand our efforts to accumulate CGM patient data and metrics and apply predictive
modeling and machine learning to generate interactive CGM insights that can inform patient behavior. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development timelines
depend on our ability to achieve clinical endpoints, regulatory and legal requirements and to overcome technology challenges. Product development timelines may be delayed due to extended regulatory approval timelines, scheduling issues with patients
and investigators, requests from institutional review boards, sensor performance and manufacturing supply constraints, among other factors. In addition, support of these clinical trials requires significant resources from employees involved in the
production of our products, including research and development, manufacturing, quality assurance, and clinical and regulatory personnel. Even if our development and clinical trial efforts are successful, the FDA may not approve our products, and
even if approved, we may not achieve acceptance in the marketplace by physicians and people with diabetes. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in Delaware in May 1999. Our principal offices are located at 6340 Sequence Drive, San Diego, California 92121, and our
telephone number is (858) <FONT STYLE="white-space:nowrap">200-0200.</FONT> Our common stock trades on The Nasdaq Global Select Market under the symbol &#147;DXCM.&#148; Our website address is www.dexcom.com. The information found on, or accessible
through, our website is not a part of this prospectus. References in this prospectus to our website are inactive textual references only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DexCom, the DexCom logo, DexCom G4, DexCom G5, DexCom G6 and DexCom SHARE are registered U.S. trademarks owned by DexCom. Other service marks,
trademarks and trade names referred to in this prospectus supplement and accompanying prospectus are the property of their respective owners. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx649190_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties referenced below and
described in the documents incorporated by reference in this prospectus supplement and accompanying prospectus, as well as other information we include or incorporate by reference herein or therein, before making an investment decision. Our
business, financial condition or results of operations could be materially adversely affected by the materialization of any of these risks. The trading price of our securities could decline due to the materialization of any of these risks, and you
may lose all or part of your investment. This prospectus supplement, accompanying prospectus and the documents incorporated herein and therein by reference also contain forward-looking statements that involve risks and uncertainties. Actual results
could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks described in the documents incorporated herein by reference, including (i)&nbsp;our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017 and our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2018, each of which is on file with the
SEC and incorporated by reference into this prospectus supplement, and (ii)&nbsp;other documents we file with the SEC that are deemed incorporated by reference into this prospectus supplement<I>.</I> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx649190_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference into this prospectus supplement contain forward-looking statements.
Forward-looking statements include all statements that are not historical facts and can be identified by the words &#147;believe,&#148; &#147;may,&#148; &#147;will,&#148; &#147;potentially,&#148; &#147;estimate,&#148; &#147;continue,&#148;
&#147;anticipate,&#148; &#147;intend,&#148; &#147;could,&#148; &#147;would,&#148; &#147;project,&#148; &#147;plan,&#148; &#147;expect,&#148; and similar expressions that convey uncertainty of future events or outcomes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in and
incorporated by reference under the heading &#147;Risk Factors&#148; and elsewhere in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein. Moreover, we operate in a very competitive
and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this
prospectus supplement may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in
the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation
to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations, except as required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus supplement, accompanying prospectus and the documents
incorporated by reference into this prospectus and the documents that we reference in this prospectus supplement and have filed with the SEC as exhibits to the registration statement of which this prospectus supplement is a part, with the
understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx649190_5"></A>DESCRIPTION OF AMENDED AND RESTATED COLLABORATION AND LICENSE
AGREEMENT AND COMMON STOCK PURCHASE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;20, 2018, we will enter into a Collaboration and License Agreement
with Verily and we will enter into the Purchase Agreement with Verily and Onduo. Pursuant to the Collaboration and License Agreement, which will amend and restate the existing Collaboration and License Agreement, dated as of August&nbsp;10, 2015 and
amended as of October&nbsp;25, 2016, or the Original Agreement, we and Verily will agree to continue to jointly develop a series of next-generation continuous glucose monitoring products. Under the terms of the Collaboration and License Agreement,
we will agree to pay an upfront fee of $250&nbsp;million, or the Upfront Fee, in cash or shares of our common stock, at our election, of which $15&nbsp;million in cash or shares of our common stock will be paid directly to Verily and, at
Verily&#146;s direction, $235&nbsp;million in cash or shares of our common stock will be paid to Onduo. We intend to elect in the Purchase Agreement to pay the Upfront Fee in shares of our common stock. The Upfront Fee will equal an aggregate of
1,840,943 shares, which number of shares was calculated based on the volume weighted average trading price of our common stock during the period of fifteen (15)&nbsp;consecutive trading days ending on the date of the Collaboration and License
Agreement. Of the Upfront Fee, 110,457 shares will be issued to Verily and 1,730,486 shares will be issued to Onduo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
pursuant to the Collaboration and License Agreement and the Purchase Agreement, we will pay Verily and Onduo up to an aggregate of $280&nbsp;million, or the Milestone Fees, in additional milestone payments upon achievement of various development,
regulatory and revenue milestones, which payments will be made directly to Verily and/or to Onduo. $275&nbsp;million of the Milestone Fees may be paid in cash or shares of our common stock, at our election, and, if made in shares of our common
stock, shall equal an aggregate of 2,025,036 shares, or Milestone Shares, which number of shares was calculated based on the volume weighted average trading price during the period of fifteen (15)&nbsp;consecutive trading days ending on the date of
the Collaboration and License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any such shares will be issued pursuant to the Purchase Agreement, which will contain, among
other things, closing procedures for issuing the shares, representations and warranties of the parties, and conditions to closing customary for agreements of this type, including the receipt of any authorization, approval, clearance or waiting
period expiration or termination that is required in connection with the issuance of the Upfront Shares or any Milestone Shares under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated
thereunder, or any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> antitrust, merger control or competition law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Collaboration and
License Agreement will provide us with certain licenses to use certain intellectual property of Verily in the field of glucose monitoring products. The royalty payments set forth in the Original Agreement will be eliminated in the Collaboration and
License Agreement, and we will not owe any royalties pursuant to the terms of the Collaboration and License Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Collaboration and License Agreement will provide that it shall continue until
December&nbsp;31, 2028, provided, that, upon achievement of the first revenue milestone event and our payment of the corresponding Milestone Fees, the term shall be extended until December&nbsp;31, 2033, and shall be terminable by either party upon
uncured material breach of the Collaboration and License Agreement by the other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Either party will be able to assign the
Collaboration and License Agreement, without the written consent of the other party, to an affiliate or to an entity that acquires all or substantially all of the business or assets of such party to which the Collaboration and License Agreement
pertains (whether by merger, reorganization, acquisition, sale or otherwise), and agrees in writing to be bound by the terms and conditions of the Collaboration and License Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx649190_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As set forth under &#147;Description of Amended and Restated Collaboration and License Agreement and Common Stock Purchase Agreement,&#148; we
will enter into the Collaboration and License Agreement with Verily. Pursuant to the Collaboration and License Agreement, we and Verily will agree to continue to jointly develop a series of next-generation continuous glucose monitoring products. The
purpose of this offering is to register the shares that may be issued pursuant to the terms of the Collaboration and License Agreement and the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not receive any proceeds from the sale of the shares of common stock covered by this prospectus. We have agreed to pay all costs
relating to the registration of the shares of our common stock covered by this prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx649190_7"></A>PLAN OF
DISTRIBUTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of the Collaboration and License Agreement and the Purchase Agreement, as an upfront
payment, we will agree to issue 110,457 shares and 1,730,486&nbsp;shares of our common stock to Verily and Onduo, respectively, subject to satisfaction of conditions to closing customary for agreements of this type. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the achievement of certain milestones set forth in the Collaboration and License Agreement and subject to our option to elect to pay cash
instead of issuing shares with respect to an aggregate of up to 2,025,036 shares of our common stock and following the satisfaction of conditions to closing customary for agreements of this type, we will agree to issue an aggregate of up to
368,189&nbsp;shares and up to 1,656,847&nbsp;shares of our common stock to Verily and Onduo, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We determined the price per
share of the common stock through negotiations with Verily. No party has acted as an underwriter or placement agent in connection with the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock that may be issued in this offering will be listed on The Nasdaq Global Select Market.&nbsp;The shares of common
stock will be delivered only in book-entry form on the records of our transfer agent only upon our election to issue shares of our common stock and following the satisfaction of conditions to closing customary for agreements of this type. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expenses directly related to this offering are estimated to be approximately $150,000 and will be paid by us. Expenses of the offering
include our SEC registration fee, legal and accounting fees and expenses and transfer agent fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx649190_8"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities offered hereby will be passed upon for us by Fenwick&nbsp;&amp; West LLP, San Francisco, California. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx649190_9"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements and schedule
included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2017, as set forth in their
reports, which are incorporated by reference in this prospectus supplement and elsewhere in the registration statement. Our financial statements and schedule are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s reports,
given on their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx649190_10"></A>WHERE YOU CAN FIND MORE INFORMATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act with
respect to the securities offered hereby. This prospectus supplement, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement, the exhibits filed therewith or the
documents incorporated by reference therein. For further information about us and the securities offered hereby, reference is made to the registration statement, the exhibits filed therewith and the documents incorporated by reference therein.
Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and in each instance we refer you to the copy of such
contract or other document filed as an exhibit to the registration statement. The SEC maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The
address of the website is www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain a website at www.dexcom.com. You may access these materials free of charge as
soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on our website is not a part of this prospectus and the inclusion of our website address in this prospectus is an inactive
textual reference only. You may also inspect these documents at our corporate headquarters at 6340 Sequence Drive, San Diego, California 92121, during normal business hours. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx649190_11"></A>INCORPORATION OF DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference the information and reports we file with it, which means that we can disclose important
information to you by referring you to these documents. The information incorporated by reference is an important part of this prospectus supplement and the accompanying prospectus, and information that we file later with the SEC will automatically
update and supersede the information already incorporated by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate by reference into this prospectus and the
registration statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC (Commission <FONT STYLE="white-space:nowrap">File&nbsp;No.&nbsp;001-51222):</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the fiscal year ended
December&nbsp;31, 2017, filed on February&nbsp;27, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Proxy Statement on Schedule 14A for our 2018 Annual Meeting of Stockholders, filed on April&nbsp;20, 2018;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the quarters ended
March&nbsp;31, 2018, June&nbsp;30, 2018, and September&nbsp;30, 2018, filed on May&nbsp;2, 2018, August&nbsp;1, 2018 and November&nbsp;6, 2018, respectively; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed on March&nbsp;14, 2018,
June&nbsp;4, 2018 and August&nbsp;1, 2018 (film no. 18985140) (and expressly not incorporating the Form <FONT STYLE="white-space:nowrap">8-K</FONT> furnished on August&nbsp;1, 2018, film no. 18984755). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon request, we will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus supplement
and accompanying prospectus is delivered, a copy of the documents incorporated by reference into this prospectus supplement and accompanying prospectus but not delivered with the prospectus supplement. You may request a copy of these filings, and
any exhibits we have specifically incorporated by reference as an exhibit in this prospectus, at no cost, by writing or telephoning us at 6340 Sequence Drive, San Diego, California 92121;
<FONT STYLE="white-space:nowrap">(858)&nbsp;200-0200.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may also access these documents, free of charge on the SEC&#146;s website
at www.sec.gov or on our website at www.dexcom.com. Information contained on our website is not incorporated by reference into this prospectus supplement or the accompanying prospectus, and you should not consider any information on, or that can be
accessed from, our website as part of this prospectus supplement or the accompanying prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement is part of a
registration statement we filed with the SEC. We have incorporated exhibits into this registration statement. You should read the exhibits carefully for provisions that may be important to you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information incorporated by reference or provided in this prospectus supplement or the accompanying prospectus. We
have not authorized anyone to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus supplement, the
accompanying prospectus or in the documents incorporated by reference herein or therein is accurate as of any date other than the date of those respective documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g655295g79z31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Debt
Securities </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Subscription Rights </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may from time to time issue, in
one or more series or classes, our common stock, preferred stock, debt securities, warrants, subscription rights and/or units in one or more offerings. We may offer these securities separately or together in units, and we may offer securities as may
be issuable upon conversion, redemption, repurchase, exchange or exercise of any of the securities registered hereunder, including any applicable anti-dilution provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides a general description of the securities we may offer. Each time we offer securities, we will specify in the
accompanying prospectus supplement the terms of the securities being offered. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any free writing
prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by
reference, before you invest in our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell these securities to or through underwriters and also to other purchasers or
through agents. We will set forth the names of any underwriters or agents, and any fees, conversions or discount arrangements, in the accompanying prospectus supplement. We may not sell any securities under this prospectus without delivery of the
applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on The Nasdaq Global Select Market under the symbol &#147;DXCM.&#148; On
November&nbsp;19, 2018, the closing price for our common stock, as reported on The Nasdaq Global Select Market, was $121.31 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties referenced under the
heading &#147;<A HREF="#toc655295_3">Risk Factors</A>&#148; contained in this prospectus beginning on page 6 and any applicable prospectus supplement, and under similar headings in the other documents that are incorporated by reference into this
prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to offer or sell securities unless accompanied by a prospectus supplement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this Prospectus is November 20, 2018. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_2">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_4">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_6">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_7">Description of Debt Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_8">Description of Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_9">Description of Subscription Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_10">Description of Units</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_11">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_12">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_13">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_14">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc655295_15">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc655295_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of an automatic registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the
United States Securities and Exchange Commission, or the SEC, using a &#147;shelf&#148; registration process as a &#147;well-known seasoned issuer&#148; as defined in Rule 405 under the Securities Act of 1933, as amended, or the Securities Act.
Under this shelf registration process, we may, from time to time, sell any combination of the securities described in this prospectus in one or more offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide one or
more prospectus supplements that will contain specific information about the terms of the offering. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and
any free writing prospectus may also add, update or change information contained in this prospectus. You should read this prospectus, the accompanying prospectus supplement and any free writing prospectus together with the additional information
described under the heading &#147;Where You Can Find More Information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in or
incorporated by reference in this prospectus, any accompanying prospectus supplement or in any related free writing prospectus filed by us with the SEC. We have not authorized anyone to provide you with different information. This prospectus and the
accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in the accompanying prospectus supplement or an offer to sell or the solicitation of an
offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any
related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the
actual documents for complete information. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you
may obtain copies of those documents as described below under the heading &#147;Where You Can Find More Information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unless the
context otherwise indicates, references in this prospectus to &#147;DexCom&#148;, &#147;we&#148;, &#147;our&#148;, &#147;us&#148; and &#147;the Company&#148; refer, collectively, to DexCom, Inc., a Delaware corporation.</I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own various U.S. federal trademark registrations and applications and unregistered trademarks, including our corporate logo. This
prospectus and the information incorporated herein by reference contains references to trademarks, service marks and trade names referred to in this prospectus and the information incorporated herein, including logos, artwork, and other visual
displays, may appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or <SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> symbols, but such references are not intended to indicate, in any way, that we will not assert, to
the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, service marks or trade names. We do not intend our use or display of other companies&#146; trade names, service marks or trademarks to
imply a relationship with, or endorsement or sponsorship of us by, any other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus, any applicable prospectus supplement or any related
free writing prospectus are the property of their respective owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc655295_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained in other parts of this prospectus or incorporated by reference in this prospectus from our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, and our other filings with the SEC listed below under the heading &#147;Incorporation of Certain Information by Reference.&#148; This
summary does not contain all of the information you should consider in making your investment decision. Before deciding to invest in our securities, you should read the entire prospectus, the applicable prospectus supplement and any related free
writing prospectus, and the information incorporated by reference herein in their entirety. You should carefully consider, among other things, the matters discussed under the heading &#147;Risk Factors&#148; contained in the applicable prospectus
supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. Some of the statements in this prospectus constitute forward-looking statements that
involve risks and uncertainties. See &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM,
systems for use by people with diabetes and by healthcare providers for the treatment of people with diabetes. We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006, and launched our latest
generation system, the DexCom G6<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Continuous Glucose Monitoring System, or G6, this year. We believe our CGM systems are currently the most consistently accurate available for continuous
glucose monitoring. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>DexCom G6<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2018, we received approval from the FDA for the G6, which is indicated by the FDA for use as both a standalone CGM and for integration
into automated insulin dosing (AID) systems. The G6 is the first CGM to receive this classification from the FDA. Along with this classification, the FDA is establishing criteria, called special controls, which outline requirements for assuring CGM
accuracy, reliability and clinical relevance, as well as describe the type of studies and data required to demonstrate acceptable CGM performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The G6 is designed to allow our transmitter to run the Software 505 algorithm, and to communicate directly to a patient&#146;s mobile device,
including iPhone<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, iPod touch<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, iPad<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, or certain Android mobile digital
devices. The G6 transmitter has a labeled useful life of three months. Data from the G6 can be integrated with DexCom CLARITY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, our cloud-based reporting software, for personalized, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">easy-to-understand</FONT></FONT> analysis of trends that may improve diabetes management. In June 2018, we received Conformit&eacute; Europ&eacute;enne Marking, or CE Mark, approval for the
G6, which allows us to sell the system in the European Union, Australia, New Zealand and the countries in Asia and Latin America that recognize the CE Mark. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sensor is inserted by the user and is intended to be used continuously for up to ten days, after which it may be replaced with a new
disposable sensor. Our transmitter is reusable until it reaches the end of its battery life. Our receiver is reusable. As we establish an installed base of customers using our products, we expect to generate an increasing portion of our revenues
through recurring sales of our disposable sensors. The G6 carries forward important features of prior generation DexCom CGM systems: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Continuous Glucose Readings:</B> Automatically sends glucose readings to a DexCom receiver or compatible smart
device every five minutes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Mobile App and Sharing:</B> Compatibility with smart device applications allows for sharing glucose
information with up to five people for added support. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Customizable Alarms and Alerts:</B> Personalized alert schedule immediately warns the wearer of pending
dangerous high and low blood sugars. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Coverage:</B> The G6 is covered by commercial insurers that reimburse for the G5 Mobile as well as Medicare.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The G6 also has a number of new or improved features compared to our prior generation devices: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Fingerstick Elimination:</B> No fingersticks are needed for calibration or diabetes treatment decisions.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Easy Sensor Applicator</B>: Complete redesign of the sensor applicator allows for <FONT
STYLE="white-space:nowrap">one-touch,</FONT> simple insertion. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Discreet and Low Profile:</B> A redesigned transmitter with a 28% lower profile than previous generation
DexCom CGMs makes the device comfortable and easy to wear under clothing. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Acetaminophen Blocking:</B> New feature allows for more accurate glucose readings with no medication
interference. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Predictive Low Alert</B>: New alert feature predicts hypoglycemia before it hits to help avoid dangerous low
blood sugar events. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Extended <FONT STYLE="white-space:nowrap">10-Day</FONT> Sensor</B>:
<FONT STYLE="white-space:nowrap">10-day</FONT> sensor allows for 43% longer wear than previous generation DexCom CGMs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except with respect to the foregoing, the G6 is equivalent to our prior generation CGM systems in its technical capabilities and its
regulatory requirements and indications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>DexCom G5<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Mobile </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2015, we received approval from the FDA for the DexCom G5<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Mobile Continuous
Glucose Monitoring System, also referred to as the G5 Mobile. As with the G6, the G5 Mobile is designed to allow our transmitter to run the Software 505 algorithm, and to communicate directly to a patient&#146;s mobile device, including iPhone<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, iPod touch<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, iPad<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, or certain Android mobile digital devices. The G5 Mobile
transmitter has a labeled useful life of three months. Data from the G5 Mobile can be integrated with DexCom CLARITY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>. In September 2015, we launched the G5 Mobile in certain countries in Europe.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to the G6, the sensor is inserted by the user and is intended to be used continuously for up to seven days, after which it may be
replaced with a new disposable sensor. Our transmitter is reusable until it reaches the end of its battery life. Our receiver is reusable. In December 2016, the FDA approved the G5 Mobile as the first CGM system in the United States to have a <FONT
STYLE="white-space:nowrap">non-adjunctive</FONT> indication. The <FONT STYLE="white-space:nowrap">non-adjunctive</FONT> indication expands the lawfully permitted use of the G5 Mobile as a replacement to finger stick glucose testing for diabetes
treatment decisions. With the new label indication, the G5 Mobile only requires two finger pricks per day for calibration. In the countries and regions outside of the United States that recognize the CE Mark, as well as the United States and Canada,
the G5 Mobile also does not require confirmatory finger sticks when making treatment decisions, although a minimum of two finger sticks a day remain necessary for calibration. Approval of the <FONT STYLE="white-space:nowrap">non-adjunctive</FONT>
indication also was an important and necessary step in enabling people with Medicare to access CGM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except with respect to the foregoing,
the G5 Mobile is equivalent to our other generation CGM systems in its technical capabilities and its regulatory requirements and indications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>DexCom G4<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> PLATINUM </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DexCom G4 PLATINUM CGM system replaced our DexCom SEVEN PLUS system beginning in 2012, when it was approved for up to seven days of
continuous use by adults with diabetes. Since 2012, we have marketed the DexCom G4 PLATINUM under a CE Mark in the European Union, Australia, New Zealand and the countries in Asia and Latin America that recognize the CE Mark, and in the United
States with approval from the FDA. We received approvals for a pediatric indication under the CE Mark in February 2013 and from the FDA in February 2014, enabling us to market and sell this system to persons two years old and older who have
diabetes. In June 2014, we received approval from the FDA for an expanded indication for the DexCom G4 PLATINUM for professional use, which allows healthcare professionals to purchase the DexCom G4 PLATINUM system for use with multiple patients.
Healthcare professionals can use the insights gained from a DexCom G4 PLATINUM professional session to adjust therapy and to educate and motivate patients to modify their behavior after viewing the effects that specific foods, exercise, stress and
medications have on their glucose levels. In October 2014, we launched our Software 505 for the DexCom G4 PLATINUM, an algorithm which enabled our systems to achieve a single digit MARD - a measure of the accuracy of continuous glucose monitoring.
<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>DexCom Share<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2015, we received approval from the FDA for the DexCom G4 PLATINUM with Share and began commercializing this product in the United States in
the first quarter of 2015 using a secure wireless connection between a patient&#146;s G4 PLATINUM receiver and an app. We now offer this feature directly from the transmitter through the G6 and the G5 Mobile apps. The DexCom Share remote monitoring
system uses an app on the patient&#146;s iPhone, iPod touch, iPad, Apple Watch<I><SUP STYLE="font-size:85%; vertical-align:top">TM</SUP></I> or Android mobile digital device to transmit glucose information to apps on the mobile devices of up to five
designated recipients, or &#147;followers&#148;, who can remotely monitor a patient&#146;s glucose information and receive alert notifications anywhere they have an Internet or cellular connection. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Data&nbsp;&amp; Insulin Delivery Collaborations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into multiple collaboration agreements that leverage our technology platform to integrate our continuous glucose monitoring
products with insulin delivery systems. The general purpose of these development and commercial relationships is to integrate our technology into the insulin pump or pen product offerings of the respective partner, enabling the partner&#146;s
insulin delivery device to receive and display glucose readings from our transmitter and, in some cases, use the glucose readings for semi-automated insulin delivery. Currently, we have announced material insulin delivery partnerships with Eli
Lilly, Insulet, Novo Nordisk and Tandem. In addition to these major partners, we are working with other companies that are pursuing varying strategies surrounding semi-automated insulin delivery and data analytics to improve outcomes and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ease-of-use</FONT></FONT> in diabetes management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Verily Collaboration
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2015, we entered into a Collaboration and License Agreement, or the Verily Collaboration Agreement, with Google Life
Sciences LLC, now named Verily Life Sciences LLC, or Verily. Pursuant to the Verily Collaboration Agreement, we and Verily have agreed to jointly develop a series of next-generation continuous glucose monitoring products. The Verily Collaboration
Agreement provides us with an exclusive license to use certain intellectual property of Verily related to the development, manufacture and commercialization of the products contemplated under the Verily Collaboration Agreement. The Verily
Collaboration Agreement provides for the establishment of a joint steering committee, joint development committee and joint commercialization committee to oversee and coordinate the parties&#146; activities under the collaboration. We and Verily
have agreed to make committee decisions by consensus. Certain amendments were made to this agreement in October 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Future Products
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to develop future generations of technologies focused on improved performance and convenience and that will enable intelligent
insulin administration. We also are aggressively exploring how to extend our product portfolio to other categories of people with diabetes including those with Type 2 diabetes that are <FONT STYLE="white-space:nowrap">non-insulin</FONT> using,
people with <FONT STYLE="white-space:nowrap">pre-diabetes</FONT> and people who are obese. Over the longer term, we plan to develop networked platforms with open architecture, connectivity and transmitters capable of communicating with other devices
and software systems. We also intend to expand our efforts to accumulate CGM patient data and metrics and apply predictive modeling and machine learning to generate interactive CGM insights that can inform patient behavior. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development timelines depend on our ability to achieve clinical endpoints, regulatory and legal requirements and to overcome
technology challenges. Product development timelines may be delayed due to extended regulatory approval timelines, scheduling issues with patients and investigators, requests from institutional review boards, sensor performance and manufacturing
supply constraints, among other factors. In addition, support of these clinical trials requires significant resources from employees involved in the production of our products, including research and development, manufacturing, quality assurance,
and clinical and regulatory personnel. Even if our development and clinical trial efforts are successful, the FDA may not approve our products, and even if approved, we may not achieve acceptance in the marketplace by physicians and people with
diabetes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Securities We May Offer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With this prospectus, we may from time to time issue, in one or more series or classes, our common stock, preferred stock, debt securities,
warrants, subscription rights and/or units in one or more offerings. We may offer these securities separately or together in units, and we may offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any
of the securities registered hereunder, including any applicable anti-dilution provisions. Each time we offer securities, we will specify in the accompanying prospectus supplement the terms of the securities being offered. The following is a summary
of the securities we may offer with this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer shares of our common stock, par value $0.001 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer shares of our preferred stock, par value $0.001 per share, in one or more series. Our board of directors or a committee designated
by the board will determine the dividend, voting, conversion and other rights of the series of shares of preferred stock being offered. Each series of preferred stock will be more fully described in the particular prospectus supplement that will
accompany this prospectus, including redemption provisions, rights in the event of our liquidation, dissolution or the winding up, voting rights and rights to convert into common stock. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Debt Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer general obligations, which may be secured or unsecured, senior or subordinated and convertible into shares of our common stock or
preferred stock. In this prospectus, we refer to the senior debt securities and the subordinated debt securities together as the &#147;debt securities.&#148; Our board of directors will determine the terms of each series of debt securities being
offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities under an indenture between us and a trustee. In this document, we have summarized general
features of the debt securities from the indenture. We encourage you to read the indenture, which is an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may
offer warrants for the purchase of debt securities, shares of preferred stock or shares of common stock. We may issue warrants independently or together with other securities. Our board of directors will determine the terms of the warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Subscription Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer subscription rights for the purchase of common stock, preferred stock or debt securities. We may issue subscription rights
independently or together with other securities. Our board of directors will determine the terms of the subscription rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Units
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer units consisting of some or all of the securities described above, in any combination, including common stock,
preferred stock, warrants and/or debt securities. The terms of these units will be set forth in a prospectus supplement. The description of the terms of these units in the related prospectus supplement will not be complete. You should refer to the
applicable form of unit and unit agreement for complete information with respect to these units. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in Delaware in May 1999. Our principal offices are located at 6340 Sequence Drive, San Diego, California 92121, and our
telephone number is (858) <FONT STYLE="white-space:nowrap">200-0200.</FONT> Our common stock trades on The Nasdaq Global Select Market under the symbol &#147;DXCM.&#148; Our website address is www.dexcom.com. The information found on, or accessible
through, our website is not a part of this prospectus. References in this prospectus to our website are inactive textual references only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DexCom, the DexCom logo, DexCom G4, DexCom G5, DexCom G6 and DexCom SHARE are registered U.S. trademarks owned by DexCom. Other service marks,
trademarks and trade names referred to in this prospectus supplement and accompanying prospectus are the property of their respective owners. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc655295_3"></A><A NAME="cov655295_1a"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties referenced below and
described in the documents incorporated by reference in this prospectus and any prospectus supplement, as well as other information we include or incorporate by reference into this prospectus and any applicable prospectus supplement, before making
an investment decision. Our business, financial condition or results of operations could be materially adversely affected by the materialization of any of these risks. The trading price of our securities could decline due to the materialization of
any of these risks, and you may lose all or part of your investment. This prospectus and the documents incorporated herein by reference also contain forward-looking statements that involve risks and uncertainties. Actual results could differ
materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks described in the documents incorporated herein by reference, including (i)&nbsp;our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017 and our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2018, each of which is on file with the
SEC and incorporated by reference into this prospectus, and (ii)&nbsp;other documents we file with the SEC that are deemed incorporated by reference into this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc655295_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference into this prospectus contain forward-looking statements. Forward-looking
statements include all statements that are not historical facts and can be identified by the words &#147;believe,&#148; &#147;may,&#148; &#147;will,&#148; &#147;potentially,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148;
&#147;intend,&#148; &#147;could,&#148; &#147;would,&#148; &#147;project,&#148; &#147;plan,&#148; &#147;expect,&#148; and similar expressions that convey uncertainty of future events or outcomes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in and
incorporated by reference under the heading &#147;Risk Factors.&#148; Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks,
nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of
these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the
expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur.
We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations, except as required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus, the documents incorporated by reference into this prospectus and the documents that we reference in this
prospectus and have filed with the SEC as exhibits to the registration statement of which this prospectus is a part, with the understanding that our actual future results, levels of activity, performance and events and circumstances may be
materially different from what we expect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc655295_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will retain broad discretion over the use of the net proceeds to us from the sale of our securities under this prospectus. Unless otherwise
provided in the applicable prospectus supplement, we intend to use the net proceeds from the sale of securities under this prospectus for general corporate purposes, which may include funding research and development of our product candidates,
expanding our manufacturing capabilities, increasing our working capital, acquisitions or investments in businesses, products or technologies that are complementary to our own and capital expenditures. We will set forth in the prospectus supplement
our intended use for the net proceeds received from the sale of any securities. Pending the application of the net proceeds, we intend to invest the net proceeds in short-term or long-term, investment-grade, interest-bearing securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc655295_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock
consists of 200,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares of undesignated preferred stock, $0.001 par value per share. As of November&nbsp;1, 2018, there were 88,844,345 shares of our common stock outstanding,
and no shares of preferred stock outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividend rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock are entitled to
receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Voting rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not
provided for cumulative voting for the election of directors in our restated certificate of incorporation. Accordingly, holders of a majority of the shares of our common stock are able to elect all of our directors. Our restated certificate of
incorporation establishes a classified board of directors, divided into three classes with staggered three-year terms. Only one class of directors is elected at each annual meeting of our stockholders, with the other classes continuing for the
remainder of their respective three-year terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>No preemptive or similar rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Right to receive liquidation distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon our liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> the assets legally available for distribution to our
stockholders would be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of
and the payment of liquidation preferences, if any, on any outstanding shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue from time to time up to 5,000,000 shares of
preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of their qualifications,
limitations or restrictions, in each case without further vote or action by our stockholders. Our board of directors is also be able to increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of
that series then outstanding, without any further vote or action by our stockholders. Our board of directors may be able to authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or
other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or
preventing a change in control of our company and might adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. We have no current plan to issue any shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions
of Delaware law, our restated certificate of incorporation and our restated bylaws could have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, may
have the effect of discouraging takeover bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our
potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law, or DGCL, regulating corporate takeovers. In
general, DGCL Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years following the date on which the person became an interested stockholder
unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the date of the transaction, the board of directors of the corporation approved either the business
combination or the transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (i)&nbsp;shares owned by persons who are directors and also officers and
(ii)&nbsp;shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or subsequent to the date of the transaction, the business combination is approved by the board of directors
of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66.67% of the outstanding voting stock that is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, a business combination includes a merger, asset or stock sale, or other transaction or series of
transactions together resulting in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested
stockholder status, did own 15% or more of a corporation&#146;s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We
also anticipate that DGCL Section&nbsp;203 may also discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Restated Certificate of Incorporation and Restated Bylaws Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation and our restated bylaws include a number of provisions that could deter hostile takeovers or delay or
prevent changes in control of our company, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Board of directors vacancies.</B> Our restated certificate of incorporation and restated bylaws authorize only
our board of directors to fill vacant directorships, including newly created seats. In addition, the number of directors constituting our board of directors is permitted to be set only by a resolution adopted by a majority vote of our entire board
of directors. These provisions would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult
to change the composition of our board of directors but promotes continuity of management. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Classified board.</B> Our restated certificate of incorporation and restated bylaws provide that our board of
directors will be classified into three classes of directors, each with staggered three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time
consuming for stockholders to replace a majority of the directors on a classified board of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Stockholder action; special meetings of stockholders.</B> Our restated certificate of incorporation provides
that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of our capital stock would not be able to amend our restated
bylaws or remove directors without holding a meeting of our stockholders called in accordance with our restated bylaws. Further, our restated bylaws and restated certificate of incorporation provide that special meetings of our stockholders may be
called only by a majority of our board of directors, the chairman of our board of directors, our Chief Executive Officer, our President or our Lead Independent Director, thus prohibiting a stockholder from calling a special meeting. These provisions
might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advance notice requirements for stockholder proposals and director nominations.</B> Our restated bylaws
provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our restated bylaws also specify
certain requirements regarding the form and content of a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
stockholder&#146;s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual
meeting of stockholders if the proper procedures are not followed. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of directors or
otherwise attempting to obtain control of our company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>No cumulative voting.</B> The Delaware General Corporation Law provides that stockholders are not entitled to
the right to cumulate votes in the election of directors unless a corporation&#146;s certificate of incorporation provides otherwise. Our restated certificate of incorporation does not provide for cumulative voting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Directors removed only for cause.</B> Our restated certificate of incorporation provides that stockholders may
remove directors only for cause and only by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of our outstanding common stock. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Issuance of undesignated preferred stock.</B> Our board of directors has the authority, without further action
by the stockholders, to issue up to 5,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of
preferred stock would enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or other means. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is
listed on The Nasdaq Global Select Market under the symbol &#147;DXCM.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC. The transfer agent&#146;s
address is 6201 15th Avenue, Brooklyn, New York 11219, and its telephone number is (800) <FONT STYLE="white-space:nowrap">937-5449.</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc655295_7"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt
securities offered by this prospectus and any accompanying prospectus supplement under an indenture to be entered into between us and the trustee identified in the applicable prospectus supplement. The terms of the debt securities will include those
stated in the indenture and those made part of the indenture by reference to the Trust Indenture Act of 1939, as in effect on the date of the indenture. We have filed a copy of the form of indenture as an exhibit to the registration statement in
which this prospectus is included. The indenture will be subject to and governed by the terms of the Trust Indenture Act of 1939. Unless otherwise specified in the applicable prospectus supplement, the debt securities will represent our direct,
unsecured obligations and will rank equally with all of our other unsecured indebtedness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the debt securities in one or more
series with the same or various maturities, at par, at a premium, or at a discount. We will describe the particular terms of each series of debt securities in a prospectus supplement relating to that series, which we will file with the SEC. The
prospectus supplement relating to the particular series of debt securities being offered will specify the particular amounts, prices and terms of those debt securities. These terms may include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate principal amount, and, if a series, the total amount authorized and the total amount outstanding;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issue price or prices, expressed as a percentage of the aggregate principal amount of the debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit on the aggregate principal amount; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates on which principal is payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate or rates (which may be fixed or variable) or, if applicable, the method used to determine such
rate or rates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates from which interest, if any, will be payable and any regular record date for the interest
payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where principal and, if applicable, premium and interest, is payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions upon which we may, or the holders may require us to, redeem or repurchase the debt
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which such debt securities may be issuable, if other than denominations of $1,000 or any
integral multiple of that number; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities are to be issuable in the form of certificated securities (as described below) or
global securities (as described below); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the portion of principal amount that will be payable upon declaration of acceleration of the maturity date if
other than the principal amount of the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of denomination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the currency, currencies or currency units in which payment of principal and, if applicable,
premium and interest, will be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if payments of principal and, if applicable, premium or interest, on the debt securities are to be made in one or
more currencies or currency units other than the currency of denomination, the manner in which the exchange rate with respect to such payments will be determined; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if amounts of principal and, if applicable, premium and interest may be determined by reference to an index based
on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index, then the manner in which such amounts will be determined; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions, if any, relating to any collateral provided for such debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to or change in the covenants and/or the acceleration provisions described in this prospectus or in
the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any events of default, if not otherwise described below under &#147;Events of Default&#148;;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, for conversion into or exchange for shares of our common stock or preferred
stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, upon which the debt securities shall be subordinated in right of payment to our
other indebtedness. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue discount debt securities that provide for an amount less than the stated
principal amount to be due and payable upon acceleration of the maturity of such debt securities in accordance with the terms of the indenture. We may also issue debt securities in bearer form, with or without coupons. If we issue discount debt
securities or debt securities in bearer form, we will describe material U.S. federal income tax considerations and other material special considerations which apply to these debt securities in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities denominated in or payable in a foreign currency or currencies or a foreign currency unit or units. If we do, we
will describe the restrictions, elections, and general tax considerations relating to the debt securities and the foreign currency or currencies or foreign currency unit or units in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt securities offered under this prospectus and any prospectus supplement will be subordinated in right of payment to certain of our
outstanding senior indebtedness. In addition, we will seek the consent of the holders of any such senior indebtedness prior to issuing any debt securities under this prospectus to the extent required by the agreements evidencing such senior
indebtedness. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registrar and Paying Agent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities may be presented for registration of transfer or for exchange at the corporate trust office of the security registrar or at
any other office or agency that we maintain for those purposes. In addition, the debt securities may be presented for payment of principal, interest and any premium at the office of the paying agent or at any office or agency that we maintain for
those purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt securities may be convertible into or exchangeable for shares of our common stock. The terms and conditions of conversion or exchange will
be stated in the applicable prospectus supplement. The terms will include, among others, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion or exchange price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion or exchange period; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provisions regarding the convertibility or exchangeability of the debt securities, including who may convert or
exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">events requiring adjustment to the conversion or exchange price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provisions affecting conversion or exchange in the event of our redemption of the debt securities; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any anti-dilution provisions, if applicable. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registered Global Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we
decide to issue debt securities in the form of one or more global securities, then we will register the global securities in the name of the depositary for the global securities or the nominee of the depositary, and the global securities will be
delivered by the trustee to the depositary for credit to the accounts of the holders of beneficial interests in the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
prospectus supplement will describe the specific terms of the depositary arrangement for debt securities of a series that are issued in global form. None of us, the trustee, any payment agent or the security registrar will have any responsibility or
liability for any aspect of the records relating to or payments made on account of beneficial ownership interests in a global debt security or for maintaining, supervising or reviewing any records relating to these beneficial ownership interests.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Protection in the Event of Change of Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture does not have any covenants or other provisions providing for a put or increased interest or otherwise that would afford holders
of our debt securities additional protection in the event of a recapitalization transaction, a change of control or a highly leveraged transaction. If we offer any covenants or provisions of this type with respect to any debt securities covered by
this prospectus, we will describe them in the applicable prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in this prospectus or the applicable prospectus supplement, our debt securities will not have the benefit of any
covenants that limit or restrict our business or operations, the pledging of our assets or the incurrence by us of indebtedness. We will describe in the applicable prospectus supplement any material covenants in respect of a series of debt
securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Merger, Consolidation or Sale of Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The form of indenture provides that we will not consolidate with or merge into any other person or convey, transfer, sell or lease our
properties and assets substantially as an entirety to any person, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are the surviving person of such merger or consolidation, or if we are not the surviving person, the person
formed by the consolidation or into or with which we are merged or the person to which our properties and assets are conveyed, transferred, sold or leased, is a corporation organized and existing under the laws of the U.S., any state or the District
of Columbia or a corporation or comparable legal entity organized under the laws of a foreign jurisdiction and has expressly assumed all of our obligations, including the payment of the principal of and, premium, if any, and interest on the debt
securities and the performance of the other covenants under the indenture; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately before and immediately after giving effect to the transaction on a pro forma basis, no event of
default, and no event which, after notice or lapse of time or both, would become an event of default, has occurred and is continuing under the indenture. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise
specified in the applicable prospectus supplement, the following events will be events of default under the indenture with respect to debt securities of any series: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we fail to pay any principal or premium, if any, when it becomes due; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we fail to pay any interest within 30 days after it becomes due; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we fail to observe or perform any other covenant in the debt securities or the indenture for 60 days after
written notice specifying the failure from the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding debt securities of that series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain events involving bankruptcy, insolvency or reorganization of us or any of our significant subsidiaries.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trustee may withhold notice to the holders of the debt securities of any series of any default, except in payment
of principal of or premium, if any, or interest on the debt securities of a series, if the trustee considers it to be in the best interest of the holders of the debt securities of that series to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default (other than an event of default resulting from certain events of bankruptcy, insolvency or reorganization) occurs, and
is continuing, then the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding debt securities of any series may accelerate the maturity of the debt securities. If this happens, the entire principal amount, plus
the premium, if any, of all the outstanding debt securities of the affected series plus accrued interest to the date of acceleration will be immediately due and payable. At any time after the acceleration, but before a judgment or decree based on
such acceleration is obtained by the trustee, the holders of a majority in aggregate principal amount of outstanding debt securities of such series may rescind and annul such acceleration if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all events of default (other than nonpayment of accelerated principal, premium or interest) have been cured or
waived; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all lawful interest on overdue interest and overdue principal has been paid; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rescission would not conflict with any judgment or decree. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if the acceleration occurs at any time when we have outstanding indebtedness that is senior to the debt securities, the payment
of the principal amount of outstanding debt securities may be subordinated in right of payment to the prior payment of any amounts due under the senior indebtedness, in which case the holders of debt securities will be entitled to payment under the
terms prescribed in the instruments evidencing the senior indebtedness and the indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default resulting from certain
events of bankruptcy, insolvency or reorganization occurs, the principal, premium and interest amount with respect to all of the debt securities of any series will be due and payable immediately without any declaration or other act on the part of
the trustee or the holders of the debt securities of that series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt
securities of a series will have the right to waive any existing default or compliance with any provision of the indenture or the debt securities of that series and to direct the time, method and place of conducting any proceeding for any remedy
available to the trustee, subject to certain limitations specified in the indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No holder of any debt security of a series will have any right to institute any proceeding
with respect to the indenture or for any remedy under the indenture, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder gives to the trustee written notice of a continuing event of default; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of the affected
series make a written request and offer reasonable indemnity to the trustee to institute a proceeding as trustee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trustee fails to institute a proceeding within 60 days after such request; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of a majority in aggregate principal amount of the outstanding debt securities of the affected series
do not give the trustee a direction inconsistent with such request during such <FONT STYLE="white-space:nowrap">60-day</FONT> period. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations do not, however, apply to a suit instituted for payment on debt securities of any series on or after the due dates expressed
in the debt securities. <B></B>We will periodically deliver certificates to the trustee regarding our compliance with our obligations under the indenture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification and Waiver </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to
time, we and the trustee may, without the consent of holders of the debt securities of one or more series, amend the indenture or the debt securities of one or more series, or supplement the indenture, for certain specified purposes, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide that the surviving entity following a change of control permitted under the indenture will assume all
of our obligations under the indenture and debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for certificated debt securities in addition to uncertificated debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with any requirements of the SEC under the Trust Indenture Act of 1939; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of debt securities of any series
as permitted by the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency, or make any other change that does not materially and adversely
affect the rights of any holder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to appoint a successor trustee under the indenture with respect to one or more series. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time we and the trustee may, with the consent of holders of at least a majority in principal amount of an outstanding series of
debt securities, amend or supplement the indenture or the debt securities series, or waive compliance in a particular instance by us with any provision of the indenture or the debt securities. We may not, however, without the consent of each holder
affected by such action, modify or supplement the indenture or the debt securities or waive compliance with any provision of the indenture or the debt securities in order to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the amount of debt securities whose holders must consent to an amendment, supplement, or waiver to the
indenture or such debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the rate of or change the time for payment of interest or reduce the amount of or postpone the date for
payment of sinking fund or analogous obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal of or change the stated maturity of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any debt security payable in money other than that stated in the debt security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change the amount or time of any payment required or reduce the premium payable upon any redemption, or change
the time before which no such redemption may be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a default in the payment of the principal of, premium, if any, or interest on the debt securities or a
redemption payment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a redemption payment with respect to any debt securities or change any provision with respect to redemption
of debt securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">take any other action otherwise prohibited by the indenture to be taken without the consent of each holder
affected by the action. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance of Debt Securities and Certain Covenants in Certain Circumstances </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture permits us, at any time, to elect to discharge our obligations with respect to one or more series of debt securities by following
certain procedures described in the indenture. These procedures will allow us either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to defease and be discharged from any and all of our obligations with respect to any debt securities except for
the following obligations (which discharge is referred to as &#147;legal defeasance&#148;): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to register the transfer or exchange of such debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to replace temporary or mutilated, destroyed, lost or stolen debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to compensate and indemnify the trustee; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to maintain an office or agency in respect of the debt securities and to hold monies for payment in trust; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to be released from our obligations with respect to the debt securities under certain covenants contained in the
indenture, as well as any additional covenants which may be contained in the applicable supplemental indenture (which release is referred to as &#147;covenant defeasance&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to exercise either defeasance option, we must irrevocably deposit with the trustee or other qualifying trustee, in trust for that
purpose: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">money; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. Government Obligations (as described below) or Foreign Government Obligations (as described below) that
through the scheduled payment of principal and interest in accordance with their terms will provide money; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of money and/or U.S. Government Obligations and/or Foreign Government Obligations sufficient in the
written opinion of a nationally-recognized firm of independent accountants to provide money; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">that, in each case
specified above, provides a sufficient amount to pay the principal of, premium, if any, and interest, if any, on the debt securities of the series, on the scheduled due dates or on a selected date of redemption in accordance with the terms of the
indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, defeasance may be effected only if, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of either legal or covenant defeasance, we deliver to the trustee an opinion of counsel, as specified
in the indenture, stating that as a result of the defeasance neither the trust nor the trustee will be required to register as an investment company under the Investment Company Act of 1940; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of legal defeasance, we deliver to the trustee an opinion of counsel stating that we have received
from, or there has been published by, the Internal Revenue Service a ruling to the effect that, or there has been a change in any applicable federal income tax law with the effect that (and the opinion shall confirm that), the holders of outstanding
debt securities will not recognize income, gain or loss for U.S. federal income tax purposes solely as a result of such legal defeasance and will be subject to U.S. federal income tax on the same amounts, in the same manner, including as a result of
prepayment, and at the same times as would have been the case if legal defeasance had not occurred; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of covenant defeasance, we deliver to the trustee an opinion of counsel to the effect that the
holders of the outstanding debt securities will not recognize income, gain or loss for U.S. federal income tax purposes as a result of covenant defeasance and will be subject to U.S. federal income tax on the same amounts, in the same manner and at
the same times as would have been the case if covenant defeasance had not occurred; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain other conditions described in the indenture are satisfied. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with our remaining obligations under the indenture and applicable supplemental indenture after a covenant defeasance of
the indenture and applicable supplemental indenture, and the debt securities are declared due and payable because of the occurrence of any undefeased event of default, the amount of money and/or U.S. Government Obligations and/or Foreign Government
Obligations on deposit with the trustee could be insufficient to pay amounts due under the debt securities of the affected series at the time of acceleration. We will, however, remain liable in respect of these payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;U.S. Government Obligations&#148; as used in the above discussion means securities that are direct obligations of or <FONT
STYLE="white-space:nowrap">non-callable</FONT> obligations guaranteed by the United States of America for the payment of which obligation or guarantee the full faith and credit of the United States of America is pledged. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Foreign Government Obligations&#148; as used in the above discussion means,
with respect to debt securities of any series that are denominated in a currency other than U.S. dollars, (1)&nbsp;direct obligations of the government that issued or caused to be issued such currency for the payment of which obligations its full
faith and credit is pledged or (2)&nbsp;obligations of a person controlled or supervised by or acting as an agent or instrumentality of such government the timely payment of which is unconditionally guaranteed as a full faith and credit obligation
by that government, which in either case under clauses (1)&nbsp;or (2), are not callable or redeemable at the option of the issuer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regarding the
Trustee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will identify the trustee with respect to any series of debt securities in the prospectus supplement relating to the
applicable debt securities. You should note that if the trustee becomes a creditor of ours, the indenture and the Trust Indenture Act of 1939 limit the rights of the trustee to obtain payment of claims in certain cases, or to realize on certain
property received in respect of any such claim, as security or otherwise. The trustee and its affiliates may engage in, and will be permitted to continue to engage in, other transactions with us and our affiliates. If, however, the trustee acquires
any &#147;conflicting interest&#148; within the meaning of the Trust Indenture Act of 1939, it must eliminate such conflict or resign. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the then outstanding debt securities of any series may direct the time, method and place of
conducting any proceeding for exercising any remedy available to the trustee. If an event of default occurs and is continuing, the trustee, in the exercise of its rights and powers, must use the degree of care and skill of a prudent person in the
conduct of his or her own affairs. Subject to that provision, the trustee will be under no obligation to exercise any of its rights or powers under the indenture at the request of any of the holders of the debt securities, unless they have offered
to the trustee reasonable indemnity or security. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Individual Liability of Incorporators, Stockholders, Officers or Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that no incorporator and no past, present or future stockholder, officer or director of our company or any successor
corporation in those capacities will have any individual liability for any of our obligations, covenants or agreements under the debt securities or such indenture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures and the
debt securities will be governed by, and construed in accordance with, the laws of the State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc655295_8"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants for the
purchase of our debt securities, preferred stock, common stock, or any combination thereof. Warrants may be issued independently or together with our debt securities, preferred stock or common stock and may be attached to or separate from any
offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and a bank or trust company, as warrant agent. The warrant agent will act solely as our agent in connection with the
warrants. The warrant agent will not have any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants. This summary of certain provisions of the warrants is not complete. For the terms of a particular
series of warrants, you should refer to the prospectus supplement for that series of warrants and the warrant agreement for that particular series. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Debt Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement
relating to a particular issue of warrants to purchase debt securities will describe the terms of the debt warrants, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the debt warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price for the debt warrants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate number of the debt warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of the debt securities, including any conversion rights, purchasable upon exercise of
the debt warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date from and after which the debt warrants and any debt securities issued with them will be
separately transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise
price for the warrants, which may be payable in cash, securities or other property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the debt warrants will commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of the debt warrants that may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt warrants represented by the debt warrant certificates or debt securities that may be issued upon
exercise of the debt warrants will be issued in registered or bearer form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information with respect to book-entry procedures, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currency units in which the offering price, if any, and the exercise price are payable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, a discussion of material U.S. federal income tax considerations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anti-dilution provisions of the debt warrants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the redemption or call provisions, if any, applicable to the debt warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions with respect to the holder&#146;s right to require us to repurchase the debt warrants upon a
change in control or similar event; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the debt warrants, including procedures and limitations relating to the exchange,
exercise, and settlement of the debt warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt warrant certificates will be exchangeable for new debt warrant
certificates of different denominations. Debt warrants may be exercised at the corporate trust office of the warrant agent or any other office indicated in the prospectus supplement. Prior to the exercise of their debt warrants, holders of debt
warrants will not have any of the rights of holders of the debt securities purchasable upon exercise and will not be entitled to payment of principal or any premium, if any, or interest on the debt securities purchasable upon exercise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus
supplement relating to a particular series of warrants to purchase our common stock or preferred stock will describe the terms of the warrants, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price for the warrants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate number of warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of the common stock or preferred stock that may be purchased upon exercise of the
warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each security; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date from and after which the warrants and any securities issued with the warrants will be
separately transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of common stock or preferred stock that may be purchased upon exercise of a warrant and the
exercise price for the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants shall commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currency units in which the offering price, if any, and the exercise price are payable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, a discussion of material U.S. federal income tax considerations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anti-dilution provisions of the warrants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the redemption or call provisions, if any, applicable to the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions with respect to a holder&#146;s right to require us to repurchase the warrants upon a change in
control or similar event; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the warrants, including procedures and limitations relating to the exchange, exercise and
settlement of the warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of equity warrants will not be entitled: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to vote, consent, or receive dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receive notice as stockholders with respect to any meeting of stockholders for the election of our directors or
any other matter; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exercise any rights as stockholders. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc655295_9"></A>DESCRIPTION OF SUBSCRIPTION RIGHTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue subscription rights to purchase our common stock, preferred stock or debt securities. These subscription rights may be offered
independently or together with any other security offered hereby and may or may not be transferable by the stockholder receiving the subscription rights in such offering. In connection with any offering of subscription rights, we may enter into a
standby arrangement with one or more underwriters or other purchasers pursuant to which the underwriters or other purchasers may be required to purchase any securities remaining unsubscribed for after such offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to any subscription rights we offer, if any, will, to the extent applicable, include specific terms
relating to the offering, including some or all of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price, if any, for the subscription rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exercise price payable for our common stock, preferred stock or debt securities upon the exercise of the
subscription rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of subscription rights to be issued to each stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and terms of our common stock, preferred stock or debt securities which may be purchased per each
subscription right; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which the subscription rights are transferable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the subscription rights, including the terms, procedures and limitations relating to the
exchange and exercise of the subscription rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the subscription rights shall commence, and the date on which the
subscription rights shall expire; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which the subscription rights may include an over-subscription privilege with respect to
unsubscribed securities or an over-allotment privilege to the extent the securities are fully subscribed; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the material terms of any standby underwriting or purchase arrangement which may be entered into
by us in connection with the offering of subscription rights. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The description in the applicable prospectus supplement
of any subscription rights we offer will not necessarily be complete and will be qualified in its entirety by reference to the applicable subscription rights certificate, which will be filed with the SEC if we offer subscription rights. We urge you
to read the applicable subscription rights certificate and any applicable prospectus supplement in their entirety. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc655295_10"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units consisting of some or all of the securities described above, in any combination, including common stock, preferred stock,
warrants and/or debt securities. The terms of these units will be set forth in a prospectus supplement. The description of the terms of these units in the related prospectus supplement will not be complete. You should refer to the applicable form of
unit and unit agreement for complete information with respect to these units. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc655295_11"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through underwriters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through dealers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to purchasers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in &#147;at the market offering&#148;, within the meaning of Rule 415(a)(4) of the Securities Act; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a combination of any of these methods or any other method permitted by law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may issue the securities as a dividend or distribution or in a subscription rights offering to our existing security holders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may directly solicit offers to purchase securities, or agents may be designated to solicit such offers. In the prospectus supplement
relating to such offering, we will name any agent that could be viewed as an underwriter under the Securities Act and describe any commissions that we must pay to any such agent. Any such agent will be acting on a best efforts basis for the period
of its appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis. This prospectus may be used in connection with any offering of our securities through any of these methods or other methods described in the
applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of the securities may be effected from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price, or prices, which may be changed from time to time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each prospectus supplement will describe the method of distribution of the securities and any applicable restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement with respect to the securities of a particular series will describe the terms of the offering of the securities,
including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name of the agent or any underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the public offering or purchase price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts and commissions to be allowed or paid to the agent or underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all other items constituting underwriting compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts and commissions to be allowed or paid to dealers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any exchanges on which the securities will be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any underwriters or agents are used in the sale of the securities in respect of which this prospectus is delivered, we will enter into an
underwriting agreement, sales agreement or other agreement with them at the time of sale to them, and we will set forth in the prospectus supplement relating to such offering the names of the underwriters or agents and the terms of the related
agreement with them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering of securities, we may grant to the underwriters an option to purchase additional
securities with an additional underwriting commission, as may be set forth in the accompanying prospectus supplement. If we grant any such option, the terms of such option will be set forth in the prospectus supplement for such securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a dealer is used in the sale of the securities in respect of which the prospectus is delivered, we will sell such securities to the dealer,
as principal. The dealer, who may be deemed to be an &#147;underwriter&#148; as that term is defined in the Securities Act, may then resell such securities to the public at varying prices to be determined by such dealer at the time of resale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we offer securities in a subscription rights offering to our existing security holders, we may enter into a standby underwriting agreement
with dealers, acting as standby underwriters. We may pay the standby underwriters a commitment fee for the securities they commit to purchase on a standby basis. If we do not enter into a standby underwriting arrangement, we may retain a
dealer-manager to manage a subscription rights offering for us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Agents, underwriters, dealers and other persons may be entitled under agreements which they
may enter into with us to indemnification by us against certain civil liabilities, including liabilities under the Securities Act, and may be customers of, engage in transactions with or perform services for us in the ordinary course of business.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If so indicated in the applicable prospectus supplement, we will authorize underwriters or other persons acting as our agents to solicit
offers by certain institutions to purchase securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in the prospectus supplement. Each contract will be for an amount not less than, and the
aggregate amount of securities sold pursuant to such contracts shall not be less nor more than, the respective amounts stated in the prospectus supplement. Institutions with whom the contracts, when authorized, may be made include commercial and
savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and other institutions, but shall in all cases be subject to our approval. Delayed delivery contracts will not be subject to any
conditions except that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase by an institution of the securities covered under that contract shall not at the time of delivery be
prohibited under the laws of the jurisdiction to which that institution is subject; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are also being sold to underwriters acting as principals for their own account, the
underwriters shall have purchased such securities not sold for delayed delivery. The underwriters and other persons acting as our agents will not have any responsibility in respect of the validity or performance of delayed delivery contracts.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Offered securities may also be offered and sold, if so indicated in the prospectus supplement, in connection with a
remarketing upon their purchase, in accordance with a redemption or repayment pursuant to their terms, or otherwise, by one or more remarketing firms, acting as principals for their own accounts or as agents for us. Any remarketing firm will be
identified and the terms of its agreement, if any, with us and its compensation will be described in the applicable prospectus supplement. Remarketing firms may be deemed to be underwriters in connection with their remarketing of offered securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain agents, underwriters and dealers, and their associates and affiliates, may be customers of, have borrowing relationships with,
engage in other transactions with, or perform services, including investment banking services, for us or one or more of our respective affiliates in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the securities, any underwriters may engage in transactions that stabilize, maintain or otherwise
affect the price of the securities or any other securities the prices of which may be used to determine payments on such securities. Specifically, any underwriters may overallot in connection with the offering, creating a short position for their
own accounts. In addition, to cover overallotments or to stabilize the price of the securities or of any such other securities, the underwriters may bid for, and purchase, the securities or any such other securities in the open market. Finally, in
any offering of the securities through a syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the securities in the offering if the syndicate repurchases
previously distributed securities in transactions to cover syndicate short positions, in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market price of the securities above independent market levels.
Any such underwriters are not required to engage in these activities and may end any of these activities at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may engage in at
the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. In addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third
parties in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement,
including in short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us in
settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in the applicable prospectus supplement (or
a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities short using this prospectus and an applicable prospectus supplement. Such
financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Rule <FONT STYLE="white-space:nowrap">15c6-1</FONT> of the Exchange Act, trades in the
secondary market generally are required to settle in two business days, unless the parties to any such trade expressly agree otherwise or the securities are sold by us to an underwriter in a firm commitment underwritten offering. The applicable
prospectus supplement may provide that the original issue date for your securities may be more than two scheduled business days after the trade date for your securities. Accordingly, in such a case, if you wish to trade securities on any date prior
to the second business day before the original issue date for your securities, you will be required, by virtue of the fact that your securities initially are expected to settle in more than two scheduled business days after the trade date for your
securities, to make alternative settlement arrangements to prevent a failed settlement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be new issues of securities
and may have no established trading market. The securities may or may not be listed on a national securities exchange. We can make no assurance as to the liquidity of or the existence of trading markets for any of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The specific terms of any <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions in respect of any given offering will be described in the
applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters, dealers and agents may engage in transactions with us, or perform services for us, in
the ordinary course of business for which they receive compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The anticipated date of delivery of offered securities will be set
forth in the applicable prospectus supplement relating to each offer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc655295_12"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain legal matters in connection with this offering will be passed upon for us by Fenwick&nbsp;&amp; West LLP, San Francisco, California.
Any underwriters will also be advised about the validity of the securities and other legal matters by their own counsel, which will be named in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc655295_13"></A>EXPERTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements and schedule
included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2017, as set forth in their
reports, which are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements and schedule are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s reports, given on their
authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc655295_14"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act with respect
to the securities offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement, the exhibits filed therewith or the documents incorporated by
reference therein. For further information about us and the securities offered hereby, reference is made to the registration statement, the exhibits filed therewith and the documents incorporated by reference therein. Statements contained in this
prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and in each instance we refer you to the copy of such contract or other document filed as
an exhibit to the registration statement. The SEC maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the website is
www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain a website at www.dexcom.com. You may access these materials free of charge as soon as reasonably
practicable after they are electronically filed with, or furnished to, the SEC. Information contained on our website is not a part of this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only.
You may also inspect these documents at our corporate headquarters at 6340 Sequence Drive, San Diego, California 92121, during normal business hours. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc655295_15"></A>INCORPORATION BY REFERENCE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference the information and reports we file with it, which means that we can disclose important
information to you by referring you to these documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede the information
already incorporated by reference. We are incorporating by reference the documents listed below, which we have already filed with the SEC, and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act,
including all filings made after the date of the filing of this registration statement and prior to the effectiveness of this registration statement, except as to any portion of any future report or document that is not deemed filed under such
provisions, after the date of this prospectus and prior to the termination of this offering: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the fiscal year ended
December&nbsp;31, 2017, filed on February&nbsp;27, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Proxy Statement on Schedule 14A for our 2018 Annual Meeting of Stockholders, filed on April&nbsp;20, 2018;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the quarters ended
March&nbsp;31, 2018, June&nbsp;30, 2018, and September&nbsp;30, 2018, filed on May&nbsp;2, 2018, August&nbsp;1, 2018 and November&nbsp;6, 2018, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed on March&nbsp;14, 2018,
June&nbsp;4, 2018 and August&nbsp;1, 2018 (film no. 18985140) (and expressly not incorporating the Form <FONT STYLE="white-space:nowrap">8-K</FONT> furnished on August&nbsp;1, 2018, film no. 18984755). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon request, we will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus is delivered,
a copy of the documents incorporated by reference into this prospectus but not delivered with the prospectus. You may request a copy of these filings, and any exhibits we have specifically incorporated by reference as an exhibit in this prospectus,
at no cost, by writing or telephoning us at 6340 Sequence Drive, San Diego, California 92121; <FONT STYLE="white-space:nowrap">(858)&nbsp;200-0200.</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may also access these documents, free of charge on the SEC&#146;s website at www.sec.gov
or on our website at www.dexcom.com. Information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information on, or that can be accessed from, our website as part of this prospectus or
any accompanying prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we filed with the SEC. We have incorporated
exhibits into this registration statement. You should read the exhibits carefully for provisions that may be important to you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should
rely only on the information incorporated by reference or provided in this prospectus or any prospectus supplement. We have not authorized anyone to provide you with different information. We are not making an offer of these securities in any state
where the offer is not permitted. You should not assume that the information in this prospectus or in the documents incorporated by reference is accurate as of any date other than the date on the front of this prospectus or those documents. </P>
<P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g649190g14l76.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>3,865,979 Shares of Common Stock </B></P>
<P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>November&nbsp;20, 2018 </B></P>
<P STYLE="margin-top:100pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus
supplement or accompanying prospectus. You must not rely on any unauthorized information or representations. This prospectus supplement is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is
lawful to do so. The information contained in this prospectus supplement is current only as of its date. </B></P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g649190g14l76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g649190g14l76.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X0?Q17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    ;    <@$R  (    4    C8=I  0    !    I    -    $L
M 0   2P    !061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W, ,C Q.#HQ,3HR
M," Q-#HS-#HT.        Z !  ,    !__\  * "  0    !    ;J #  0
M   !    &@         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   :[
M     $@    !    2     '_V/_@ !!*1DE&  $" 0!( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ &@!N P$B  (1 0,1 ?_=  0
M!__$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M! T       0    >.$))3009       $    'CA"24T#\P      "0
M     0 X0DE-! H       $  #A"24TG$       "@ !          (X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      V$    &
M       :    ;@   !8 1 !E '@ 8P!O &T 7P!/ &X 90!? %, = !E '
M7P!! &@ 90!A &0 ,0    $                          0
M    ;@   !H                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   !H     4F=H=&QO;F<   !N    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<    :     %)G
M:'1L;VYG    ;@    -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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MZRQI -#Y>2*^#N+3L?\ 1)<WA&R_Z5C_ -'Y_P -_.<C^C_RD/(_F3_1./\
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M6_LS[=L&[9ZFR?S)W<_O>D@/^C=_0>&?2XY;_/?^BE>_[2?X/^;_ .M?1_\
M//\ WQ&/N6;/0UI'=0XNK__9 #A"24T$(0      4P    $!    #P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !( 00!D &\ 8@!E "  4 !H
M &\ = !O ', : !O '  ( !# %,    ! #A"24T$!@      !P (     0$
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# __  !$( !H
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MA:>XD>F'>H,,0?4B :])):H.WJ\O.9>;TY<CO)(=MC8JP0T+%5+.Q]3^%:U
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MS_\ F1G_ #)_<?\ Q9_^/>_S6U?^/._[\_\ \[+_ &C['W,5G_R3]G_Y(?\
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,Q_YM?#_U;_Y]Z__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g655295g79z31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g655295g79z31.jpg
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M]"\AB,=4KC\6K$7^PV?&TG64H6\)Y?: ;,Q,?66!^7BS6CRSZ'X%ZMN?IKS
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I)%0,Z 9#OM-NR<"0I!*I),J @99)I(%,[]1 :! ['_)+KF6<8V6/_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
